Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...

Legend Biotech (NASDAQ: LEGN) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...

A high-security federal lab tucked into South San Francisco’s life-sciences hub is suddenly up for grabs, with a price tag ...

The increase in nationwide vacancy to 23.2% is a reversal from the slight dip to end 2025, according to preliminary CBRE data ...

The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.

But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...